Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial

NCT04333472 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT04333472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Can-Fite BioPharma
Phase
Phase 2
Overall status
Completed
Start date
January 6, 2021
Completion date
April 21, 2022
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, covid-19